Endpoints News looked into earnings call transcripts to find information nuggets on biopharma manufacturing plans. We discovered that Merck and Sanofi are both aiming to manage market demand, while Takeda and Novartis are trying to address manufacturing constraints and access.
Merck is ramping up manufacturing capacity at two facilities to…
Click here to view original post
